# COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

> **NCT05075538** · PHASE4 · TERMINATED · sponsor: **Jules Bordet Institute** · enrollment: 152 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** Spikevax
- **BIOLOGICAL:** Comirnaty
- **BIOLOGICAL:** Spikevax bivalent Original/Omicron BA.1
- **BIOLOGICAL:** Spikevax bivalent Original/Omicron BA.4-5
- **BIOLOGICAL:** Comirnaty Original/Omicron BA.1
- **BIOLOGICAL:** Comirnaty Original/Omicron BA.4-5
- **BIOLOGICAL:** Comirnaty Omicron XBB.1.5
- **BIOLOGICAL:** Spikevax Omicron XBB.1.5

## Key facts

- **NCT ID:** NCT05075538
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-01
- **Primary completion:** 2024-01-08
- **Final completion:** 2024-01-08
- **Target enrollment:** 152 (ACTUAL)
- **Why stopped:** The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years.
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075538, "COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05075538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*